Observational studyJNCI cancer spectrum2025

MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data.

Adam M Brufsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.